Published on : Feb 23, 2017
ALBANY, NY, Feb 23, 2017: The report is a comprehensive study of the global market for melanoma therapeutics, analyzing the key factors that expected to influence the demand in the near future.
The 81-page report understands that melanoma is a type of cancer that develops in the melanocytes, generally in moles and can severely affect the skin, called as cutaneous melanoma. However, other pigmented tissues such as eye of intestines are also prone to melanoma, known as extracutaneous melanoma. It is considered a life-threatening form of skin cancer, which remains highly prevalent and treatment-resistant among all human cancers.
Exposure to the UV light, which is partly attributed to the depleting ozone layer due to increasing pollution, is the primary factor for the growing melanoma cancer cases and thereby escalating the demand for effective therapeutics. Increased investment for the development of improved disease management, especially in the advanced metastatic setting, is another factor favoring the market. Moreover, in the past decade, several novel targeted therapies have been developed that help immune response to melanoma and this increased number of treatment options for patients is helping the market expansion. It has also been observed that despite these aggressive developments, there still are vast unmet requirement for both cutaneous and extracutaneous melanoma. In addition to that, investment in first-in-class innovation remains robust, which will further boost the market over the course of next few years.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=950607
Some of the key market dynamics explored in the report include pathophysiology of melanoma, the emergence of several new drug classes in the recent past and their impact on the treatment algorithm, and the reasons behind significant unmet needs across the globe. The report also tries to determine the most promising first-in-class targets, pipeline products that have no prior involvement in co-development deals and licensing, and the ratio of first-in-class targets to first-in-class products on the basis of different stages of development.
In the section on the case for innovation in the melanoma market, the report explores factors such as growing number of opportunities for biologic products, diversification of molecular targets, innovations in first-in-class product developments, and the shift in regulatory and reimbursement policy toward first in class product innovation. The section of clinical and commercial landscape covers disease symptoms, diagnosis, etiology, pathophysiology, epidemiology, and treatment.
The report provides an assessment of pipeline product innovation including melanoma pipeline by molecule type, stage of development, and comparative distribution programs between the melanoma market and pipeline by molecular target. It also highlights some of the recent regional and global licensing deals and strategic consolidations.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org